KR102896955B1 - 암의 검사 방법 - Google Patents

암의 검사 방법

Info

Publication number
KR102896955B1
KR102896955B1 KR1020227012018A KR20227012018A KR102896955B1 KR 102896955 B1 KR102896955 B1 KR 102896955B1 KR 1020227012018 A KR1020227012018 A KR 1020227012018A KR 20227012018 A KR20227012018 A KR 20227012018A KR 102896955 B1 KR102896955 B1 KR 102896955B1
Authority
KR
South Korea
Prior art keywords
molecule
bc2lcn
serpina3
cancer
gal3bp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227012018A
Other languages
English (en)
Korean (ko)
Other versions
KR20220079855A (ko
Inventor
히로아키 다테노
다츠야 오다
오사무 시모무라
Original Assignee
고쿠리츠켄큐카이하츠호진 상교기쥬츠 소고켄큐쇼
고쿠리쯔 다이가쿠 호징 츠쿠바 다이가쿠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고쿠리츠켄큐카이하츠호진 상교기쥬츠 소고켄큐쇼, 고쿠리쯔 다이가쿠 호징 츠쿠바 다이가쿠 filed Critical 고쿠리츠켄큐카이하츠호진 상교기쥬츠 소고켄큐쇼
Publication of KR20220079855A publication Critical patent/KR20220079855A/ko
Application granted granted Critical
Publication of KR102896955B1 publication Critical patent/KR102896955B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/574—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G01N33/548—Carbohydrates, e.g. dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8125—Alpha-1-antitrypsin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
KR1020227012018A 2019-10-11 2020-10-09 암의 검사 방법 Active KR102896955B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2019-187197 2019-10-11
JP2019187197 2019-10-11
PCT/JP2020/038300 WO2021070934A1 (ja) 2019-10-11 2020-10-09 がんの検査方法

Publications (2)

Publication Number Publication Date
KR20220079855A KR20220079855A (ko) 2022-06-14
KR102896955B1 true KR102896955B1 (ko) 2025-12-05

Family

ID=75438180

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227012018A Active KR102896955B1 (ko) 2019-10-11 2020-10-09 암의 검사 방법

Country Status (6)

Country Link
US (1) US12618842B2 (cg-RX-API-DMAC7.html)
EP (1) EP4043881A4 (cg-RX-API-DMAC7.html)
JP (1) JP7656829B2 (cg-RX-API-DMAC7.html)
KR (1) KR102896955B1 (cg-RX-API-DMAC7.html)
CN (1) CN114556101B (cg-RX-API-DMAC7.html)
WO (1) WO2021070934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022182394A (ja) * 2021-05-28 2022-12-08 独立行政法人国立病院機構 抗原固相化デバイス
WO2025187809A1 (ja) * 2024-03-08 2025-09-12 富士フイルム株式会社 検出対象物質を免疫学的に検出する方法、非特異反応を抑制する方法、フコース含有組成物、および試薬キット

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017061449A1 (ja) * 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
WO2018190357A1 (ja) * 2017-04-11 2018-10-18 国立研究開発法人産業技術総合研究所 レクチンの固定化方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
JP5977743B2 (ja) 2011-06-15 2016-08-24 三洋化成工業株式会社 磁性シリカ粒子を用いた測定方法及び該測定方法用試薬
WO2013172105A1 (ja) * 2012-05-18 2013-11-21 日東紡績株式会社 膵臓癌を検出するためのマーカー
WO2014126146A1 (ja) 2013-02-14 2014-08-21 独立行政法人産業技術総合研究所 未分化細胞除去方法
JP7386647B2 (ja) 2018-08-13 2023-11-27 東ソー株式会社 糖鎖への親和性が向上したフコース結合性タンパク質、およびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017061449A1 (ja) * 2015-10-05 2017-04-13 国立研究開発法人産業技術総合研究所 がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
WO2018190357A1 (ja) * 2017-04-11 2018-10-18 国立研究開発法人産業技術総合研究所 レクチンの固定化方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Laubli Heinz et al, Journal of Biological Chemistry (2014.11.28.), vol 289.48, pp 33481-33491.*
Zeng Xuemei et al, Journal of Proteome Research (2010.10.08.), vol 9.12, pp 6440-6449.*

Also Published As

Publication number Publication date
KR20220079855A (ko) 2022-06-14
JP7656829B2 (ja) 2025-04-04
EP4043881A1 (en) 2022-08-17
WO2021070934A1 (ja) 2021-04-15
EP4043881A4 (en) 2022-11-23
US12618842B2 (en) 2026-05-05
US20220236275A1 (en) 2022-07-28
CN114556101A (zh) 2022-05-27
JPWO2021070934A1 (cg-RX-API-DMAC7.html) 2021-04-15
CN114556101B (zh) 2025-09-26

Similar Documents

Publication Publication Date Title
CN102356316B (zh) 肝内胆管癌的检出、辨别方法
EP1137943B1 (en) Cancer detection method and reagents
JP7490007B2 (ja) レクチンベースのがんの診断
AU2013210776B2 (en) Biomarkers for gastric cancer and uses thereof
WO2022063156A1 (zh) 乳腺癌的生物标志物及其应用
EP2851688B1 (en) Use of glycoprotein C4BPA as marker for detecting pancreatic cancer
WO2022083673A1 (zh) 食管癌的生物标志物及其应用
JP2002532686A5 (cg-RX-API-DMAC7.html)
WO2022083603A1 (zh) 半胱氨酸蛋白酶抑制剂与Cathepsin复合物作为肿瘤诊断标志物的应用
US20030138860A1 (en) Cancer detection methods and reagents
WO2022083586A1 (zh) 半胱氨酸蛋白酶抑制剂sn与cathepsin l1复合物作为胃癌诊断标志物的应用
US12618842B2 (en) Cancer test method
KR101144324B1 (ko) 대장암 예후진단용 단백질 마커 디펜신?5와 rod1단백질의 조합 및 이들 각각에 대한 항체를 포함하는 대장암 예후진단키트
Fania et al. A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification
US20180188255A1 (en) Method for the in vitro diagnosis of pancreatic ductal adenocarcinoma or for determining the predisposition to pancreatic ductal adenocarcinoma
WO2021246153A1 (ja) 膵臓がんの検出方法及び検出試薬

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000